Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | TYK2 | P29597 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | WDR5 | P61964 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1767572 | 0.92 | TSHR (0.56) | JAK2TYK2NPC1SMN1; SMN2RAB9A | |
| SCHEMBL1767368 | 0.91 | NPC1 (0.59) | JAK2TYK2NPC1SMN1; SMN2RAB9A | |
| SCHEMBL1767513 | 0.89 | HTT (0.61) | NPC1SMN1; SMN2RAB9AHTTLMNA | |
| SCHEMBL1767398 | 0.86 | AURKA (0.56) | JAK2TYK2NPC1SMN1; SMN2RAB9A | |
| SCHEMBL1767414 | 0.83 | L3MBTL1 (0.60) | SMN1; SMN2HTTLMNAALDH1A1ALOX12 | |
| SCHEMBL1767801 | 0.83 | SMN1; SMN2 (0.67) | JAK2TYK2SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL1767434 | 0.83 | HDAC1 (0.60) | NPC1SMN1; SMN2RAB9AHTTLMNA | |
| SCHEMBL29941278 | 0.83 | ERCC1 (0.59) | NPC1SMN1; SMN2RAB9AHTTALDH1A1 | |
| SCHEMBL1767426 | 0.82 | KDM5B (0.60) | NPC1SMN1; SMN2RAB9AHTTLMNA | |
| SCHEMBL1767475 | 0.81 | KDM1A (0.62) | NPC1SMN1; SMN2RAB9AHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160289191-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2016-10-06 | — | — | US | disclosed |
| US-20160289191-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2016-10-06 | — | — | US | disclosed |
| US-9187426-B2 | Organic compounds | NOVARTIS AG (CH) | 2015-11-17 | — | — | US | disclosed |
| US-9187426-B2 | Organic compounds | NOVARTIS AG (CH) | 2015-11-17 | — | — | US | disclosed |
| CN-102119152-B | Organic compounds | NOVARTIS AG | 2014-07-02 | — | — | CN | disclosed |
| CN-102119152-A | Organic compounds | NOVARTIS AG | 2011-07-06 | — | — | CN | disclosed |
| US-20110105530-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2011-05-05 | — | — | US | disclosed |
| US-20110105530-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2011-05-05 | — | — | US | disclosed |
| WO-2009156484-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105530-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | JAK2 4383/4885TYK2 4187/4885NPC1 228/4885 |
| US-20160289191-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | JAK2 4383/4885TYK2 4187/4885NPC1 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.